Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.

Abed Y, Tu V, Carbonneau J, Checkmahomed L, Venable MC, Fage C, Marie-Ève-Hamelin, Dufresne SF, Kobinger G, Boivin G.

Antiviral Res. 2018 Sep 13;159:26-34. doi: 10.1016/j.antiviral.2018.09.007. [Epub ahead of print]

PMID:
30219318
2.

Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses.

Tu V, Abed Y, Fage C, Baz M, Boivin G.

Antiviral Res. 2018 Jun;154:110-115. doi: 10.1016/j.antiviral.2018.04.009. Epub 2018 Apr 16.

PMID:
29674164
3.

Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.

Fage C, Tu V, Carbonneau J, Abed Y, Boivin G.

Antivir Ther. 2017;22(8):711-716. doi: 10.3851/IMP3158.

PMID:
29082897
4.

A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.

Abed Y, Boivin G.

Open Forum Infect Dis. 2017 May 18;4(3):ofx105. doi: 10.1093/ofid/ofx105. eCollection 2017 Summer. Review.

5.

The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.

Fage C, Pizzorno A, Rhéaume C, Abed Y, Boivin G.

J Med Virol. 2017 Dec;89(12):2239-2243. doi: 10.1002/jmv.24911. Epub 2017 Aug 25.

PMID:
28792077
6.

In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site.

Retamal M, Abed Y, Rhéaume C, Baz M, Boivin G.

J Gen Virol. 2017 Jun;98(6):1224-1231. doi: 10.1099/jgv.0.000800. Epub 2017 Jun 20.

PMID:
28631598
7.

The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.

Tu V, Abed Y, Barbeau X, Carbonneau J, Fage C, Lagüe P, Boivin G.

Antiviral Res. 2017 Jan;137:6-13. doi: 10.1016/j.antiviral.2016.11.007. Epub 2016 Nov 9.

PMID:
27838351
8.

Droplet digital PCR to investigate quasi-species at codons 119 and 275 of the A(H1N1)pdm09 neuraminidase during zanamivir and oseltamivir therapies.

Abed Y, Carbonneau J, L'Huillier AG, Kaiser L, Boivin G.

J Med Virol. 2017 Apr;89(4):737-741. doi: 10.1002/jmv.24680. Epub 2016 Sep 14.

PMID:
27602879
9.

The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.

Abed Y, Bouhy X, L'Huillier AG, Rhéaume C, Pizzorno A, Retamal M, Fage C, Dubé K, Joly MH, Beaulieu E, Mallett C, Kaiser L, Boivin G.

Antiviral Res. 2016 Aug;132:6-12. doi: 10.1016/j.antiviral.2016.05.006. Epub 2016 May 13.

PMID:
27185624
10.

Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Ann J, Abed Y, Beaulieu E, Bouhy X, Joly MH, Dubé K, Carbonneau J, Hamelin ME, Mallett C, Boivin G.

Influenza Other Respir Viruses. 2016 Mar;10(2):122-6. doi: 10.1111/irv.12356. Epub 2016 Jan 29.

11.

Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.

Paradis EG, Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA.

PLoS One. 2015 May 20;10(5):e0126115. doi: 10.1371/journal.pone.0126115. eCollection 2015.

12.

E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.

L'Huillier AG, Abed Y, Petty TJ, Cordey S, Thomas Y, Bouhy X, Schibler M, Simon A, Chalandon Y, van Delden C, Zdobnov E, Boquete-Suter P, Boivin G, Kaiser L.

J Infect Dis. 2015 Dec 1;212(11):1726-34. doi: 10.1093/infdis/jiv288. Epub 2015 May 17.

13.

Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice.

Retamal M, Abed Y, Rhéaume C, Cappelletti F, Clementi N, Mancini N, Clementi M, Burioni R, Boivin G.

Antimicrob Agents Chemother. 2015 May;59(5):2647-53. doi: 10.1128/AAC.00118-15. Epub 2015 Feb 17.

14.

Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.

Abed Y, Pizzorno A, Bouhy X, Boivin G.

Antiviral Res. 2015 Feb;114:57-61. doi: 10.1016/j.antiviral.2014.12.006. Epub 2014 Dec 12.

PMID:
25512229
15.

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Pizzorno A, Abed Y, Plante PL, Carbonneau J, Baz M, Hamelin MÈ, Corbeil J, Boivin G.

Antimicrob Agents Chemother. 2014 Nov;58(11):6398-405. doi: 10.1128/AAC.02956-14. Epub 2014 Aug 11.

16.

Epitope mapping of the 2009 pandemic and the A/Brisbane/59/2007 seasonal (H1N1) influenza virus haemagglutinins using mAbs and escape mutants.

Retamal M, Abed Y, Corbeil J, Boivin G.

J Gen Virol. 2014 Nov;95(Pt 11):2377-89. doi: 10.1099/vir.0.067819-0. Epub 2014 Jul 30.

PMID:
25078301
17.

Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Samson M, Abed Y, Desrochers FM, Hamilton S, Luttick A, Tucker SP, Pryor MJ, Boivin G.

Antimicrob Agents Chemother. 2014 Sep;58(9):5220-8. doi: 10.1128/AAC.03313-14. Epub 2014 Jun 23.

18.

Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.

Pizzorno A, Abed Y, Rhéaume C, Boivin G.

Antiviral Res. 2014 May;105:54-8. doi: 10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28.

PMID:
24583158
19.

Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.

Abed Y, Pizzorno A, Bouhy X, Rhéaume C, Boivin G.

J Virol. 2014 Feb;88(3):1652-8. doi: 10.1128/JVI.02681-13. Epub 2013 Nov 20.

20.

Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis.

Roussy JF, Abed Y, Bouhy X, Boivin G.

J Clin Microbiol. 2013 Dec;51(12):4234-6. doi: 10.1128/JCM.02659-13. Epub 2013 Oct 2.

21.

Influenza virus resistance to neuraminidase inhibitors.

Samson M, Pizzorno A, Abed Y, Boivin G.

Antiviral Res. 2013 May;98(2):174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22. Review.

PMID:
23523943
22.

Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Pizzorno A, Abed Y, Rhéaume C, Bouhy X, Boivin G.

Antimicrob Agents Chemother. 2013 Apr;57(4):1784-9. doi: 10.1128/AAC.02269-12. Epub 2013 Jan 28.

23.

The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.

Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA.

J Virol. 2012 Oct;86(19):10651-60. doi: 10.1128/JVI.07244-11. Epub 2012 Jul 25.

24.

Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Abed Y, Pizzorno A, Boivin G.

Antimicrob Agents Chemother. 2012 Aug;56(8):4375-80. doi: 10.1128/AAC.00753-12. Epub 2012 Jun 4.

25.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.

Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11. Epub 2011 Dec 27.

26.

Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses.

Abed Y, Pizzorno A, Bouhy X, Boivin G.

PLoS Pathog. 2011 Dec;7(12):e1002431. doi: 10.1371/journal.ppat.1002431. Epub 2011 Dec 8.

27.

Parenteral peramivir treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses.

Abed Y, Boivin G, Yoshida R, Kodama M, Hernandez JE.

J Infect Dis. 2011 Nov 15;204(10):1641-2; author's reply 1642-3. doi: 10.1093/infdis/jir610. Epub 2011 Sep 23. No abstract available.

PMID:
21949045
28.

The 2009 pandemic H1N1 D222G hemagglutinin mutation alters receptor specificity and increases virulence in mice but not in ferrets.

Abed Y, Pizzorno A, Hamelin ME, Leung A, Joubert P, Couture C, Kobasa D, Boivin G.

J Infect Dis. 2011 Oct 1;204(7):1008-16. doi: 10.1093/infdis/jir483.

PMID:
21881115
29.

Influenza drug resistance.

Pizzorno A, Abed Y, Boivin G.

Semin Respir Crit Care Med. 2011 Aug;32(4):409-22. doi: 10.1055/s-0031-1283281. Epub 2011 Aug 19. Review.

PMID:
21858746
30.

Assessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model.

Holder BP, Simon P, Liao LE, Abed Y, Bouhy X, Beauchemin CA, Boivin G.

PLoS One. 2011 Mar 24;6(3):e14767. doi: 10.1371/journal.pone.0014767.

31.

Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Pizzorno A, Bouhy X, Abed Y, Boivin G.

J Infect Dis. 2011 Jan 1;203(1):25-31. doi: 10.1093/infdis/jiq010.

32.

The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant.

Simon P, Holder BP, Bouhy X, Abed Y, Beauchemin CA, Boivin G.

J Clin Microbiol. 2011 Feb;49(2):715-7. doi: 10.1128/JCM.01732-10. Epub 2010 Nov 24.

33.

Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets.

Hamelin ME, Baz M, Abed Y, Couture C, Joubert P, Beaulieu E, Bellerose N, Plante M, Mallett C, Schumer G, Kobinger GP, Boivin G.

PLoS Pathog. 2010 Jul 22;6(7):e1001015. doi: 10.1371/journal.ppat.1001015.

34.

Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.

Abed Y, Simon P, Boivin G.

Antimicrob Agents Chemother. 2010 Jul;54(7):2819-22. doi: 10.1128/AAC.01681-09. Epub 2010 Apr 19.

35.

Whole-genome characterization and genotyping of global WU polyomavirus strains.

Bialasiewicz S, Rockett R, Whiley DW, Abed Y, Allander T, Binks M, Boivin G, Cheng AC, Chung JY, Ferguson PE, Gilroy NM, Leach AJ, Lindau C, Rossen JW, Sorrell TC, Nissen MD, Sloots TP.

J Virol. 2010 Jun;84(12):6229-34. doi: 10.1128/JVI.02658-09. Epub 2010 Mar 31.

36.
37.

Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.

Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G.

N Engl J Med. 2009 Dec 3;361(23):2296-7. doi: 10.1056/NEJMc0910060. Epub 2009 Nov 11. No abstract available.

38.
39.

A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.

Abed Y, Baz M, Boivin G.

J Infect Dis. 2009 Jan 15;199(2):180-3. doi: 10.1086/595736.

PMID:
19046066
40.

Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.

Baz M, Abed Y, Nehmé B, Boivin G.

Antimicrob Agents Chemother. 2009 Feb;53(2):791-3. doi: 10.1128/AAC.01276-08. Epub 2008 Nov 17.

41.

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, Abed Y, Savard C, Pare C, Lopez Macias C, Boivin G, Leclerc D.

Vaccine. 2008 Jun 25;26(27-28):3395-403. doi: 10.1016/j.vaccine.2008.04.052. Epub 2008 May 12.

PMID:
18511159
42.

Human metapneumovirus infection in immunocompromised child.

Abed Y, Boivin G.

Emerg Infect Dis. 2008 May;14(5):854-6. doi: 10.3201/eid1405.071459. No abstract available.

43.

New Saffold cardioviruses in 3 children, Canada.

Abed Y, Boivin G.

Emerg Infect Dis. 2008 May;14(5):834-6. doi: 10.3201/eid1405.071675.

44.

WU polyomavirus in children, Canada.

Abed Y, Wang D, Boivin G.

Emerg Infect Dis. 2007 Dec;13(12):1939-41. doi: 10.3201/eid1312.070909.

45.

Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.

Abed Y, Nehmé B, Baz M, Boivin G.

Antiviral Res. 2008 Feb;77(2):163-6. Epub 2007 Sep 10.

PMID:
17919743
46.
48.

Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.

Baz M, Abed Y, Boivin G.

Antiviral Res. 2007 May;74(2):159-62. Epub 2006 Nov 20.

PMID:
17137644
49.

Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.

Baz M, Abed Y, McDonald J, Boivin G.

Clin Infect Dis. 2006 Dec 15;43(12):1555-61. Epub 2006 Nov 8.

PMID:
17109288
50.

Multi-year study of human metapneumovirus infection at a large US Midwestern Medical Referral Center.

Gray GC, Capuano AW, Setterquist SF, Erdman DD, Nobbs ND, Abed Y, Doern GV, Starks SE, Boivin G.

J Clin Virol. 2006 Dec;37(4):269-76. Epub 2006 Sep 27.

Supplemental Content

Loading ...
Support Center